Phase I study of selinexor, ixazomib, and low-dose dexamethasone in patients with relapsed or refractory multiple myeloma Research Letter
| Authors: | Salcedo, M.; Lendvai, N.; Mastey, D.; Schlossman, J.; Hultcrantz, M.; Korde, N.; Mailankody, S.; Lesokhin, A.; Hassoun, H.; Smith, E.; Shah, U.; Diab, V.; Werner, K.; Landau, H.; Lahoud, O.; Drullinsky, P.; Shah, G.; Chung, D.; Scordo, M.; Giralt, S.; Landgren, O. |
| Title: | Phase I study of selinexor, ixazomib, and low-dose dexamethasone in patients with relapsed or refractory multiple myeloma |
| Keywords: | adult; clinical article; aged; fatigue; neutropenia; diarrhea; drug dose reduction; drug safety; drug withdrawal; hypophosphatemia; treatment duration; cancer patient; letter; anorexia; low drug dose; multiple cycle treatment; multiple myeloma; anemia; nausea; thrombocytopenia; vomiting; cohort analysis; dexamethasone; food and drug administration; abdominal pain; alanine aminotransferase; aspartate aminotransferase; bilirubin; hyperkalemia; hyponatremia; cancer center; ondansetron; immunomodulation; maximum tolerated dose; creatinine clearance; hypocalcemia; faintness; human; male; female; ixazomib; selinexor; presyncope |
| Journal Title: | Clinical Lymphoma, Myeloma and Leukemia |
| Volume: | 20 |
| Issue: | 3 |
| ISSN: | 2152-2650 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2020-03-01 |
| Start Page: | 198 |
| End Page: | 200 |
| Language: | English |
| DOI: | 10.1016/j.clml.2019.12.013 |
| PUBMED: | 32001193 |
| PROVIDER: | scopus |
| PMCID: | PMC7405911 |
| DOI/URL: | |
| Notes: | Letter -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
